Skip to main content

Advertisement

Table 1 Characteristics of patients with early rheumatoid arthritis (RA) and undifferentiated arthritis (UA) from the ESPOIR cohort

From: Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort

  UA (n = 159) Early RA (n = 632) P value
Age 47.2 ± 13.8 48.5 ± 12.2 0.46
Women ( n ,%) 117 (74%) 492 (78%) 0.25
First symptom (months) 6.6 ± 7.7 6.9 ± 8.5 0.72
DAS28 4.0 ± 1.0 5.4 ± 1.2 <0.0001
CRP level (mg/L) 17.2 ± 29.3 21.1 ± 33.1 0.0028
ESR 25.3 ± 22.4 30.6 ± 24.9 0.0014
Positive anti-CCP antibodies ( n ,%) 2 (1.26%) 313 (49.5%) <0.0001
Positive RF ( n ,%) 5 (3.1%) 365 (57.75%) <0.0001
Swollen-joint count 3.5 ± 2.4 8.2 ± 5.2 <0.0001
Tender-joint count 3.2 ± 2.6 9.9 ± 7.2 <0.0001
HAQ score 0.69 ± 0.58 1.05 ± 0.69 <0.0001
Diabetes mellitus ( n ,%) 7 (4.4%) 24 (3.8%) 0.73
HOMA-IR index 2.5 ± 2.6 2.8 ± 4.2 0.37
BMI 24.7 ± 4.6 25.2 ± 4.6 0.22
Steroid prescription at inclusion ( n ,%) 22 (13.8%) 84 (13.3%) 0.86
Radiographic damage at inclusion ( n ,%) 0 (0) 108 (17.1%) <0.0001
Total SHS at inclusion 4.6 ± 6.8 6.14 ± 7.92 0.005
   Erosive SHS 1.6 ± 3.13 3.09 ± 4.98 <0.0001
   Narrowing SHS 2.97 ± 4.82 3.04 ± 4.36 0.77
Total SHS at 1 year 5.7 ± 9.5 7.7 ± 10.7 0.006
   Erosive SHS 2.35 ± 5.05 4.48 ± 7.56 <0.0001
   Narrowing SHS 3.36 ± 5.54 3.26 ± 4.78 0.9552
Total SHS between inclusion and 1 year 1.0 ± 3.8 1.6 ± 4.4 0.02
Erosive SHS between inclusion and 1 year 0.73 ± 2.7 1.37 ± 3.73 0.0025
Narrowing SHS between inclusion and 1 year 0.24 ± 1.22 0.26 ± 1.15 0.7294
Adiponectin level (μg/ml) 4.9 ± 3.4 5.0 ± 3.7 0.63
Leptin level (ng/ml) 14.6 ± 14.4 14.4 ± 13.7 0.74
Visfatin/NAMPT level (ng/ml) 4.1 ± 3.6 3.57 ± 3.1 0.47
  1. Data are expressed as mean ± SD unless indicated. Bold P values are significant.
  2. DAS28, Disease Activity Score in 28 joints; CRP, C-reactive protein level; ESR, erythrocyte sedimentation rate; anti-CCP, anti-cyclic citrullinated protein peptide antibodies; RF, rheumatoid factor; HAQ, Health Assessment Questionnaire; VAS, visual analog scale; BMI, body mass index; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance, SHS, total Sharp/van der Heijde score; ∆SHS, variation in SHS between inclusion and 1 year.